USGA yields 10000000.00% · ABBV yields 3.06%● Live data
📍 USGA pulled ahead of the other in Year 1
Combined, USGA + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of USGA + ABBV for your $10,000?
US Global Nanospace, Inc., a research and development company, is engaged in identifying, developing, and commercializing technologies and products for integration into the security, defense, and health and safety markets. It offers modular autonomous perimeter security and non-lethal defense system, an autonomous, intelligent, and integrated wide area perimeter security and denial system for large wide area perimeter applications, such as international and sovereign borders, oil and gas infrastructure, and other high value critical asset installations. The company also provides non-toxic decontaminant foam for the neutralization of chemical and biological weapons and contaminants; filter element materials; lightweight blast mitigation materials; castable blast mitigation products for munitions containers, munitions storage facilities, and other applications; and lightweight shielded turret for the high mobility multipurpose wheeled vehicles. In addition, it offers light weight anti-ballistic\blast fragment barrier materials; antiballistic replacement door skin products that are lightweight antiballistic panels designed to protect vehicle occupants in elevated-threat locations; cigarette filters; and radomes, a protective housing for radar antenna. It serves aerospace, homeland security, defense, transportation, construction, and industrial markets. US Global Nanospace, Inc. was founded in 2002 and is based in Carson City, Nevada.
Full USGA Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.